- Home
- UTHR
as 10-09-2025 3:47pm EST
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 20.7B | IPO Year: | 1999 |
| Target Price: | $459.60 | AVG Volume (30 days): | 846.4K |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 25.63 | EPS Growth: | 17.94 |
| 52 Week Low/High: | $266.98 - $459.48 | Next Earning Date: | 10-29-2025 |
| Revenue: | $3,077,800,000 | Revenue Growth: | 17.62% |
| Revenue Growth (this year): | 13.71% | Revenue Growth (next year): | 5.72% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 8 '25 | Sell | $451.21 | 4,000 | $1,803,449.33 | 2,030 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 7 '25 | Sell | $451.82 | 4,000 | $1,807,320.00 | 2,030 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 6 '25 | Sell | $448.21 | 4,000 | $1,798,765.00 | 2,030 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Oct 6 '25 | Sell | $432.14 | 22,500 | $10,130,438.91 | 0 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 3 '25 | Sell | $446.02 | 4,000 | $1,784,847.06 | 2,030 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 2 '25 | Sell | $434.88 | 4,000 | $1,739,525.00 | 2,030 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Oct 2 '25 | Sell | $437.12 | 11,000 | $4,802,573.67 | 46,351 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Oct 1 '25 | Sell | $425.37 | 4,000 | $1,701,796.52 | 2,030 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Sep 30 '25 | Sell | $422.84 | 4,000 | $1,691,357.60 | 2,030 | |
| ROTHBLATT MARTINE A | UTHR | Chairperson & CEO | Sep 29 '25 | Sell | $422.27 | 4,000 | $1,702,526.79 | 2,030 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
What Catalysts Are Reshaping the Narrative for United Therapeutics This Year?
Simply Wall St.
6 days ago
How Investors Are Reacting To United Therapeutics (UTHR) Positive Phase 3 Results for Tyvaso in IPF
Zacks
8 days ago
Is IPF the Next Big Market Opportunity for United Therapeutics?
Zacks
8 days ago
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
MT Newswires
8 days ago
United Therapeutics Insider Sold Shares Worth $3,393,884, According to a Recent SEC Filing
MT Newswires
20 days ago
United Therapeutics Insider Sold Shares Worth $747,768, According to a Recent SEC Filing
Business Wire
20 days ago
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary Fibrosis
StockStory
21 days ago
1 Momentum Stock to Target This Week and 2 We Brush Off
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.